文献速递肾小球疾病急性肾损伤

狼疮肾炎与ANCA相关血管炎:迈向精准医学?

Lupus nephritis and ANCA-associated vasculitis: towards precision medicine?
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

综述探讨狼疮肾炎(LN)和ANCA相关血管炎(AAV)从「一刀切」治疗向个性化精准治疗转变的进展。LN方面,更准确的病理分类和B细胞在发病中的作用为个体化治疗提供机会,钙调磷酸酶抑制剂及抗CD20抗体(利妥昔单抗、奥法木单抗)在试验中显示有效。AAV方面,靶向治疗考虑疾病严重度、ANCA抗体类型(MPO vs PR3)及副作用风险,利妥昔单抗广泛用于诱导和维持,需持久B细胞清除。分子和遗传标志物仍少纳入诊疗流程。

要点

  • LN病理分类更准确可助疾病分型和靶向治疗。
  • B细胞在LN发病中重要,抗CD20抗体和钙调磷酸酶抑制剂有效。
  • AAV治疗需考虑ANCA类型和个体差异,利妥昔单抗广泛使用。

核心结论

  • LN和AAV治疗正从统一方案向考虑个体异质性的精准医学方向演进。
  • 分子和遗传标志物仍少纳入诊断治疗算法,真正精准医学尚待实现。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 更准确可重复的LN病理分类系统可能改善疾病分类并实现更靶向治疗。
  • LN病理生理理解提示T细胞和B细胞均起重要作用,为个体化治疗提供新机会。
  • 近期试验显示钙调磷酸酶抑制剂及抗CD20抗体利妥昔单抗和奥法木单抗治疗LN有效。
  • AAV靶向治疗考虑疾病严重度、ANCA抗体类型(MPO vs PR3)及治疗副作用风险。
  • 利妥昔单抗广泛用于AAV,需持久B细胞清除以获得持久临床应答,尤其抗PR3相关病。

临床怎么用

  • LN治疗可考虑钙调磷酸酶抑制剂和抗CD20抗体作为新选择。
  • AAV治疗应区分诱导与维持,并考虑ANCA抗体类型和个体副作用风险。
  • 使用利妥昔单抗治疗AAV需追求持久B细胞清除,尤其抗PR3相关疾病。

局限性

  • 分子和遗传标志物很少纳入诊断和治疗算法,真正精准医学仍未实现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Historically the treatment of lupus nephritis (LN) and anti-neutrophil cytoplasmic antibody (ANCA) vasculitis was 'one size fits all'; however, with the emergence of precision medicine initiatives, the field is moving towards more personalized treatment approaches. The recent development of a more accurate and reproducible histopathological classification system for LN could lead to better disease categorization and therefore more targeted therapies. A better understanding of the pathophysiology of LN has provided evidence that not only T but also B cells play an important role, opening new opportunities for individualized treatment approaches. Recent trials have shown calcineurin inhibitors and the anti-CD20 antibodies rituximab and ofatumumab to be effective in the treatment of LN, adding new treatment options. State-of-the-art targeted therapy in ANCA-associated vasculitis (AAV) takes interindividual heterogeneity in disease severity, type of ANCA antibody [myeloperoxidase versus proteinase 3 (PR3)] and the risk for side effects of therapy into consideration. In addition, within an individual, induction therapy differs from maintenance therapy, the same holding true in incident and relapsing disease. Rituximab is now widely used in AAV and it has become clear that prolonged B cell depletion, as in LN, must be achieved to obtain a long-lasting clinical response, especially in anti-PR3-associated disease. Still, despite these advances, molecular and genetic markers are rarely incorporated into diagnostic and treatment algorithms and true precision medicine remains an aspiration that hopefully can be achieved.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Rosenkranz AR, Tesar V. Lupus nephritis and ANCA-associated vasculitis: towards precision medicine? Nephrol Dial Transplant. 2021. PMID: 34153980. doi:10.1093/ndt/gfab166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。